Plain-English translation of NCT06714357 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called valproic acid, when combined with two standard cancer treatments ( and ), can help people with advanced colorectal cancer live longer and respond better to therapy. Valproic acid is an existing medication that researchers believe may boost how well the cancer drugs work by helping cancer cells become more vulnerable to treatment.
Some patients with colorectal cancer eventually stop responding to anti-cancer drugs even when they initially worked well. Researchers believe that adding this medication could help 'wake up' cancer cells that have become resistant, making them responsive to treatment again.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either standard chemotherapy alone or the same chemotherapy combined with valproic acid. Treatment is given intravenously every two weeks, and you will take valproic acid as a daily oral pill with a gradual dose increase. You will continue treatment until your cancer stops responding, side effects become unacceptable, or you and your doctor decide to stop. Throughout and after treatment, you will have regular blood tests, imaging scans, and check-ins with your medical team.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
Italy